Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?-Reference-Cited by-同舟云学术

Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?

Published:2018-12-01 Issue:1 Volume:311 Page:63-69
ISSN:0340-3696
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Balighi Kamran,Daneshpazhooh Maryam,Mahmoudi HamidReza,Badakhsh Mehrnoosh,Teimourpour Amir,Ehsani Amir Houshang,Azizpour Arghavan,Akbari Zahra,Mahdavinia Mostafa,Ghasemiadl Mojtaba,Tavakolpour Soheil^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

http://link.springer.com/article/10.1007/s00403-018-1881-1/fulltext.html

Reference18 articles.

1. Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P (2009) ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 145:529–535. https://doi.org/10.1001/archdermatol.2009.9

2. Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS (2016) First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. Int Immunopharmacol 34:25–31. https://doi.org/10.1016/j.intimp.2016.02.013

3. Anandan V, Jameela WA, Sowmiya R, Kumar MMS, Lavanya P (2017) Rituximab: a magic bullet for pemphigus. J Clin Diagn Res 11:WC01–WC06. https://doi.org/10.7860/JCDR/2017/21868.9717

4. Balighi K, Sakhi RS, Daneshpazhooh M, Mahmoudi H, Teimourpour A, Tavakolpour S (2018) Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther. https://doi.org/10.1111/dth.12671

5. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P (2007) Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 143:1033–1038. https://doi.org/10.1001/archderm.143.8.1033

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center;Medicina;2024-02-04

2. Combination therapy for management of pemphigus patients with unexpected therapeutic response to rituximab: A report of five cases;Clinical Case Reports;2023-11

3. Targeting therapy in pemphigus: Where are we now and where are we going?;Heliyon;2023-06

4. Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability;Patient Preference and Adherence;2022-11

5. Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients;Dermatologic Therapy;2022-10-17